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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common
malignancy in the world (1) and the third most common
cause of death due to cancer in Korea (2). Multiple treatment
modalities are available for patients with HCC, and hepatic
resection has been successful as a treatment option with cura-
tive intent (3). However, more than 80% of patients are not
candidates for surgical resection at the time of diagnosis due
to advanced lesions and/or associated liver disease (4). In those
cases, clinicians are confronted with the difficulty of select-
ing the optimal treatment option. The usual goals of the
neoadjuvant therapy are to eradicate subclinical disease to
reduce recurrence and the tumor bulk to prevent tumor spi-
llage during operation. In the cases of large HCC greater
than 5 cm in size, neoadjuvant treatments such as transarte-
rial chemoembolization (TACE) and radiation therapy can
be performed.
Initially, TACE was performed to treat unresectable HCC
(5). Recently, TACE has been used as preoperative adjuvant
therapy in patients with resectable HCC in the hope of increas-
ing disease-free survival rates and improving long-term re-
sults after hepatectomy (6, 7). In those cases, however, the
efficacy of improving postoperative survival remains contro-
versial. Moreover, TACE alone frequently results in incom-
plete tumor necrosis (8).
Radiation therapy alone has been of limited benefit in the
treatment of HCC. However, in several reports showing the
results of HCC with combined treatment of radiation and
chemotherapy, a beneficial effect has been suggested (9, 10).
Currently, surgical resection of advanced HCC following
neoadjuvant treatment is challenging with the development
of surgical techniques. Furthermore reductive or salvage sur-
gery that resulted in the downstaging of unresectable HCC
following palliative treatment showed some benefits for sur-
vival (11, 12). For large HCC, efforts to increase the curative
rate and survival will be important in the search for various
therapeutic modalities. 
The efficacy of preoperative TACE and radiation therapy
prior to hepatic resection has not been extensively reported.
In this retrospective study, we analyzed sixteen patients with
HCC greater than 5 cm in size that underwent hepatic resec-
tion after neoadjuvant combined TACE and radiation therapy.
MATERIALS AND METHODS
Between January 1994 and May 2007, 436 patients with
HCC underwent hepatic resection. Among these patients,
16 patients with HCC of greater than 5 cm in size were given
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The Efficacy of Hepatic Resection after Neoadjuvant Transarterial
Chemoembolization (TACE) and Radiation Therapy in Hepatocellular
Carcinoma Greater Than 5 cm in Size
In cases of large hepatocellular carcinoma (HCC), neoadjuvant treatment such as
transarterial chemoembolization (TACE) and radiation therapy can be performed.
The aim of this study was to evaluate the outcome of these treatments prior to hep-
atic resection. Between January 1994 and May 2007, 16 patients with HCC greater
than 5 cm in size were treated with TACE and radiation therapy prior to hepatic resec-
tion. The clinicopathologic factors were reviewed retrospectively. Of the 16 patients,
there were 14 men and two women, and the median age was 52.5 yr. TACE was
performed three times in average, and the median radiation dosage was 45 Gy. The
median diameter of tumor on specimen was 9.0 cm. The degree of tumor necrosis
was more than 90% in 14 patients. The median survival time was 13.3 months. Five
patients had survived more than 2 yr and there were two patients who had survived
more than 5 yr. Although the prognosis of large HCC treated with neoadjuvant ther-
apy is not satisfactory, some showed long-term survival loger than 5 yr. Further
research will be required to examine the survival and disease control effect in a
prospective randomized study. 
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preoperative TACE and radiation therapy prior to hepatic
resection at Severance Hospital, Yonsei University College
of Medicine in Seoul, Korea. Medical records, histopatholo-
gy, and survival data were reviewed and analyzed retrospec-
tively. 
TACE and radiation therapy were carried out as described
below. TACE was performed with an infusion of a mixture
of 5 mL iodized oil contrast medium (Lipiodol, Guerbet,
Aulnay-sous-Bois, France) and 50 mg Adriamycin (Adri-
amycin, Ildong pharm, Seoul, Korea) and followed by em-
bolization using gelatin sponge particles (Cutanplast, Mas-
cia Bruneili Spa, Milano, Italy). 
Patients that received radiation therapy in the primary
lesion of the liver were included in the study, whereas patients
who received radiation therapy in the extrahepatic metastat-
ic organs were excluded. Simulating computed tomography
(CT) scans were taken to determine the radiation volume for
each patient, including the tumors with 2-3 cm margin. 
We investigated the effect of preoperative TACE and radi-
ation therapy through the reduction of the tumor size. We
also evaluated the level of alpha-fetoprotein (AFP), Indocya-
nine Green retention rate at 15 min (ICG-R 15), Child-Pugh
classification, operative factors, and pathologic results-tumor
size and number, the presence of vessel invasion, the extent
of tumor necrosis, and resection margin and stage according
to the Japanese TNM classification (13).
The effectiveness of preoperative therapy on tumor response
was evaluated by comparing serial CT scans before and after
treatment. The response evaluation criteria in solid tumors
(RECIST) (14) was used for evaluation of the tumor response.
The RECIST uses unidimensional measurement. Complete
disappearance of the tumor was considered as a complete res-
ponse (CR). A reduction of at least 30% in the sum of the
longest diameters of target lesions, taking as reference the
baseline study, was considered a partial response (PR). An
increase of at least 20% in the sum of the longest diameters
of target lesions, taking as reference the smallest sum of the
longest diameters recorded since treatment started or new
lesions appeared, was regarded as a progressive disease (PD).
However, neither the PR nor PD criteria were met, taking
as reference the smallest sum of the longest diameters record-
ed since treatment started was regarded as a stable disease
(SD). All patients received anatomical hepatic resections with
the goal of achieving negative resection margins. In most
patients, however, due to the cirrhosis and liver atrophy accom-
panied by huge liver mass, the achievement of enough resec-
tion margins being greater than 1 cm was difficult. 
Patients were followed up at 1 month after operation and
then every 3 months. Patients were screened for AFP, and
they underwent dynamic CT. When intrahepatic recurrence
was suspected, most of the patients underwent hepatic an-
giography or magnetic resonance imaging (MRI) to confirm
the existence of recurrence.
Statistical calculations were performed using SPSS, version
13.0 for Windows (SPSS Inc. Chicago, IL, U.S.A.). Overall
survival and recurrence rates were calculated using the Kaplan-
Meier method. 
RESULTS
The 16 patients examined in the study included 14 men
and two women with a median age of 52.5 yr (ranging from
22-70 yr). The clinicopathological characteristics of the 16
patients are shown in Table 1. Fifteen patients had hepatitis
B viral infection and 1 patient had hepatitis C viral infection.
Median numbers of TACE performed preoperatively was
three times and median radiation dosage was 45 Gy (with a
range of 30-68 Gy). The median interval between the ter-
*, Median value; 
� , This clinical staging was done after neoadjuvant ther-
apy, just before liver resection. 
AFP, alpha-fetoprotein; ICG R15, indocyanine green retention rate at
15 min; TACE, transarterial chemoembolization; CR, complete response;
PR, partial response; SD, stable disease; PD, progressive disease. 
Factor
Sex (M:F) 14:2
Age (yr) 52.5* (22-70)
Preoperative AFP (IU/mL) 13.1* (2.0-2,648.0)
Preoperative ICG R15 (%) 12.7* (1.0-22.7)
Clinical stage
�(Japanese TNM)
II 13 
III 3 
No of TACE (times) 3* (1-6)
Radiation dosage (Gy) 45* (30-68)
Response (patients)
CR 0
PR 2
SD 11
PD 3
Time interval to operation (month) 4.7* (0.6-39.1)
Operative time (min) 275* (175-630) 
Blood loss (mL) 1,000* (96-6,000)
No of tumors
11 3
22
31
Degree of necrosis
100% 10
90-95% 4
80% 1
30% 1
Resection margin (cm)
<0.5 8
0.5-1 3
≥15
Pathological stage (Japanese TNM)
II 10 
III 4 
IV A 2 
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mination of radiation therapy and hepatic resection was 4.7
months. The median tumor diameter before the neoadjuvant
therapy measured on the CT scans was 10.0 cm (with a range
of 6.3-18.0 cm). Changes in tumor size comparing the CT
scans before and after the treatment were following: size reduc-
tion was achieved in nine cases, an increase in tumor size was
noted in three cases, and four cases displayed no change. None
of the 16 patients demonstrated a CR, and only two patients
showed a PR according to RECIST criteria. The response
rate calculated for the proportion of CR and PR to 16 patients
was 12.5% in preoperative CT scan. 
All patients belonged to Child-Pugh class A before and after
treatment.The median ICG-R 15 (preoperative status) was
12.7% (and ranged from 1.0-22.7%). Seven patients showed
elevation of ICG-R 15 after treatment (ICG-R15 was not check-
ed at initial diagnosis in three patients). The median value of
AFP at initial diagnosis was 1,507.3 IU/mL (with a range from
4.4 to >50,000 IU/mL). The median value of AFP after treat-
ment (just preoperative status) was 13.1 (with a range from
2.0 to 2,648 IU/mL). Thirteen patients demonstrated more
than 50% decrease of AFP levels after treatment. Two patients
demonstrated elevation of AFP levels after treatment. 
Various surgical procedures were performed, including
right hemihepatectomy (n=8), left hemihepatectomy (n=4),
central bisectionectomy (n=1), trisegmentectomy (n=1) and
bisegmentectomy (n=2). In the cases of large tumors com-
bined with severe adhesion making difficulties in liver mobi-
lization, anterior approach rather than conventional technique
of liver mobilization was performed. 
Thirteen of 16 patients had a single tumor. The median
tumor diameter measured on the specimen was 9.0 cm (with
a range of 5-18 cm). The degree of tumor necrosis noted upon
microscopic examination was more than 80% necrosis in 15
patients. Microvessel invasion was detected in five patients.
The pathology of the remaining liver was characterized as
normal in three patients, as chronic hepatitis in eight patients,
and as cirrhosis in five patients. Ten patients had pathological
stage II tumors, four patients had stage III tumors, and two
patients had stage IVA tumors accordingt to Japanese TNM
system. Finally, the staging discrepancies were noted between
the clinical and pathological stages in five patients whose
tumor stages were upgraded due to microvessel invasion. 
Fig. 1. Overall survival curve of the 16 patients.
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*, AFP level at initial diagnosis; 
� , AFP level after TACE and radiation therapy.
TACE, transarterial chemoembolization; AFP, alpha-fetoprotein; ICG R15, indocyanine green retention rate at 15 min; SD, stable disease; PD, progressive
disease; PR, partial response.
Case Sex Age
No of
TACE
RTx
dose
(cGy)
AFP*
(IU/mL)
AFP
�
(IU/mL)
ICG
R15 (%)
Res-
ponse
No of
tumor
Necro-
sis (%)
Resection
margin
(cm)
Disease- 
free 
survival
(month)
Survival
time
(month)
Survival
Recur-
rence
1 M 44 3 5,040 8,688 19.61 14.8 SD 1 99 0.7 Yes 3.7 No 7.4
2 M 58 6 4,500 >50,000 90.19 15.0 SD 1 99 0.2 Yes 2.7 No 18.2
3 M 54 1 5,940 4,506 133 12.0 SD 2 99 1.3 Yes 3.1 No 15.6
4 F 46 1 4,500 23,189.4 59.1 11.8 SD 1 99 2.0 Yes 30.4 No 87.4
5 M 22 1 3,000 184 2.3 8.1 PD 1 99 0.3 Yes 3.4 No 8.0
6 F 46 3 6,840 3,929.2 2 5.9 SD 1 99 0.1 No 3.0 No 3.0
7 M 70 4 4,500 2,826 1,874 13.4 SD 3 30 0.25 Yes 7.7 No 28.0
8 M 46 4 4,500 >50,000 2,648 8.8 SD 2 90 0 Yes 0.9 No 5.0
9 M 63 4 5,400 4.4 11.97 13.4 SD 1 99 2.0 No 59.9 No 60.0
10 M 66 5 4,500 188.6 21.67 8.3 SD 1 90 0.5 Yes 2.0 No 9.0
11 M 54 2 5,400 61.36 2.73 14.0 PD 1 99 0.3 No 7.8 No 7.8
12 M 52 2 4,500 6.47 12.85 22.7 SD 1 80 1.0 Yes 15.5 Yes 33.1
13 M 51 3 4,500 91.31 13.44 22.1 PD 1 90 0 No 13.7 Yes 13.7
14 M 35 4 4,500 7,423.94 3.49 19.4 PR 1 99 0.3 No 11.0 Yes 11.0
15 M 58 1 4,500 15.23 2.1 4.4 SD 1 95 0.7 No 30.5 Yes 30.5
16 M 53 1 4,500 22.35 11.9 1.0 PR 1 99 3.0 No 3.0 Yes 3.0
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No postoperative mortality occurred in the cases reviewed
in this study. The mean follow-up period was 24.2 months
(with a range of 3.2-87.4 months) (Fig. 1). The median sur-
vival time was 13.3 months. The median disease-free survival
time was 5.7 months. The patterns of recurrence were intra-
hepatic (n=7) and lung (n=2), and most recurrences occurred
within 4 months of the operation. Eleven patients died due
to tumor recurrences (n=8) and hepatic failure (n=2). Five
patients survived more than 2 yr, and 2 patients survived
more than 5 yr (Table 2). The two long-term survivors showed
complete total necrosis of the tumor although 1 patient show-
ed vascular invasion of the necrotic tumor. The pathology of
remaining liver showed non-cirrhotic liver.
DISCUSSION
Several treatment modalities are available for patients with
HCC, including TACE, radiofrequency ablation, hepatic arte-
rial infusion, and radiation therapy. When adequate neoad-
juvant treatment is achieved, sequential hepatic resection
may be a valuable option for prolonging survival. However,
the main problem with these tumor-shrinking treatments is
that only a small proportion of patients respond well enough
to allow hepatic resection following therapy, and the respon-
ders cannot be predicted.
The efficacy of salvage or reductive surgery for HCC fol-
lowing adjuvant therapy has been reported by several authors
(11, 12, 15). Nevertheless, the efficacy of preoperative TACE
is controversial. Some authors have demonstrated the adverse
effects of preoperative TACE (16, 17), while others have re-
ported its efficacy (7, 18). The main limitation of TACE is
incomplete necrosis due to dual blood supply around the
capsule, multiple collateral circulation, or recanalization of
the embolized artery (19). Furthermore, patients with large
HCC can rarely achieve complete remission by TACE alone. 
To overcome the limitations associated with TACE, com-
bined treatment with radiation therapy can produce synergis-
tic effects such as the elimination of residual cancer cells fol-
lowing TACE. Tumor shrinkage after TACE allows the use
of smaller irradiation fields, which permits higher tumor doses
and improves normal liver tolerance. Furthermore, retainment
of the anticancer drug in the tumor has been documented
to have a radiosensitizing effect (20, 21).
There are few reports that have examined the patients with
HCC who underwent hepatectomy following TACE and
radiation therapy. The response rates of advanced and unre-
sectable HCC treated with only TACE and radiation thera-
py were previously reported to be 18-65.8% in the review
of the literatures (22-25). The response rate calculated by the
proportion of CR and PR according to RECIST criteria based
on CT scan was 12.5% (two of sixteen patients). However,
actually the pathologic specimen showed CR in 10 patients
(total necrosis) and PR in 5 patients (80-95% necrosis). There-
fore reduction of tumor size in imaging study did not reflect
the response to treatment exactly. 
Fourteen patients showed greater than 90% necrosis. The
role of tumor necrosis in patient prognosis remains contro-
versial. Some authors reported that the extent of necrosis was
not a favorable prognostic factor (26, 27). Other authors have
reported that preoperative TACE resulted in better disease-
free survival rates when complete tumor necrosis was induced
(28). In our study, the two patients who survived beyond 5
yr showed total tumor necrosis on the specimen. In patients
with partial necrosis, the remaining tumor cells are less firm-
ly attached and more likely to be dislodged into the blood-
stream during hepatic resection (28, 29). The residual viable
cancer cells may facilitate tumor progression and induce intra-
hepatic metastasis. Such intrahepatic recurrences are consid-
ered to arise from intrahepatic metastasis by means of venous
dissemination (30). However it is still unclear that tumor
necrosis improves the disease-free survival or the pattern of
recurrence after curative resection of HCC.
In the 16 patients who underwent hepatectomy following
TACE and radiation therapy, tumors recurred in eight cases
mostly within 4 months of the operation. The median survival
duration was 13.3 months. The results from patients with
unresectable or advanced HCC who were treated with TACE
and radiation therapy for palliation and not given surgery at
other institutions were reviewed due to rarity of hepatic resec-
tion after neoadjuvant TACE and radiation therapy. It seemed
that the result of our study did not reveal any survival bene-
fit when compared with the results of these studies (24, 31).
In the previous study in our institute, the preoperative TACE
and non-TACE group undergoing curative resection greater
than 5 cm in size did not show significant difference in dis-
ease free survival. And the 16 patients in current study did
not reveal any disease free survival benefit comparing with
these preoperative TACE and non-TACE group in our insti-
tute. And the pattern of recurrence between the TACE and
non-TACE groups undergoing curative resection did not
reveal any difference (27). 
The efficacy of hepatectomy following TACE and radia-
tion therapy was difficult to determine because the number
of patients in this study was small. In this retrospective study,
the prognosis of HCC patients who underwent hepatecto-
my following TACE and radiation therapy was not satisfac-
tory although two long term survivors were noted. Surgical
resection can be one of treatment option when the patient
did not show complete response following TACE and radia-
tion therapy. Therefore further research will be required to
examine the survival and disease control effect in a prospec-
tive randomized study. 
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